Japan · Delayed Price · Currency is JPY Nxera Pharma Statistics
Total Valuation
Nxera Pharma has a market cap or net worth of JPY 81.90 billion. The enterprise value is 118.91 billion.
| Market Cap | 81.90B |
| Enterprise Value | 118.91B |
Important Dates
The last earnings date was Friday, February 13, 2026.
| Earnings Date | Feb 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Nxera Pharma has 90.49 million shares outstanding. The number of shares has increased by 0.61% in one year.
| Current Share Class | 90.49M |
| Shares Outstanding | 90.49M |
| Shares Change (YoY) | +0.61% |
| Shares Change (QoQ) | -0.00% |
| Owned by Insiders (%) | 10.84% |
| Owned by Institutions (%) | 19.72% |
| Float | 73.19M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 16.81 |
| PS Ratio | 2.77 |
| PB Ratio | 1.34 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -9.49 |
| EV / Sales | 4.02 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -38.16 |
Financial Position
The company has a current ratio of 2.54, with a Debt / Equity ratio of 0.94.
| Current Ratio | 2.54 |
| Quick Ratio | 1.76 |
| Debt / Equity | 0.94 |
| Debt / EBITDA | n/a |
| Debt / FCF | -18.41 |
| Interest Coverage | -1.13 |
Financial Efficiency
Return on equity (ROE) is -19.35% and return on invested capital (ROIC) is -8.53%.
| Return on Equity (ROE) | -19.35% |
| Return on Assets (ROA) | -3.70% |
| Return on Invested Capital (ROIC) | -8.53% |
| Return on Capital Employed (ROCE) | -7.22% |
| Weighted Average Cost of Capital (WACC) | 6.73% |
| Revenue Per Employee | 77.53M |
| Profits Per Employee | -32.80M |
| Employee Count | 382 |
| Asset Turnover | 0.21 |
| Inventory Turnover | 0.81 |
Taxes
| Income Tax | -2.42B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +4.87% in the last 52 weeks. The beta is -0.00, so Nxera Pharma's price volatility has been lower than the market average.
| Beta (5Y) | -0.00 |
| 52-Week Price Change | +4.87% |
| 50-Day Moving Average | 852.92 |
| 200-Day Moving Average | 891.36 |
| Relative Strength Index (RSI) | 53.31 |
| Average Volume (20 Days) | 759,390 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Nxera Pharma had revenue of JPY 29.62 billion and -12.53 billion in losses. Loss per share was -138.80.
| Revenue | 29.62B |
| Gross Profit | 21.42B |
| Operating Income | -8.46B |
| Pretax Income | -14.95B |
| Net Income | -12.53B |
| EBITDA | -4.10B |
| EBIT | -8.46B |
| Loss Per Share | -138.80 |
Balance Sheet
The company has 20.37 billion in cash and 57.38 billion in debt, with a net cash position of -37.01 billion or -409.02 per share.
| Cash & Cash Equivalents | 20.37B |
| Total Debt | 57.38B |
| Net Cash | -37.01B |
| Net Cash Per Share | -409.02 |
| Equity (Book Value) | 61.00B |
| Book Value Per Share | 674.04 |
| Working Capital | 26.97B |
Cash Flow
In the last 12 months, operating cash flow was -2.67 billion and capital expenditures -448.00 million, giving a free cash flow of -3.12 billion.
| Operating Cash Flow | -2.67B |
| Capital Expenditures | -448.00M |
| Free Cash Flow | -3.12B |
| FCF Per Share | -34.43 |
Margins
Gross margin is 72.32%, with operating and profit margins of -28.58% and -42.31%.
| Gross Margin | 72.32% |
| Operating Margin | -28.58% |
| Pretax Margin | -50.48% |
| Profit Margin | -42.31% |
| EBITDA Margin | -13.83% |
| EBIT Margin | -28.58% |
| FCF Margin | n/a |
Dividends & Yields
Nxera Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.61% |
| Shareholder Yield | -0.61% |
| Earnings Yield | -15.30% |
| FCF Yield | -3.80% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on June 27, 2018. It was a forward split with a ratio of 4.
| Last Split Date | Jun 27, 2018 |
| Split Type | Forward |
| Split Ratio | 4 |
Scores
Nxera Pharma has an Altman Z-Score of 0.73 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.73 |
| Piotroski F-Score | 3 |